JP2012527440A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012527440A5 JP2012527440A5 JP2012511336A JP2012511336A JP2012527440A5 JP 2012527440 A5 JP2012527440 A5 JP 2012527440A5 JP 2012511336 A JP2012511336 A JP 2012511336A JP 2012511336 A JP2012511336 A JP 2012511336A JP 2012527440 A5 JP2012527440 A5 JP 2012527440A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- composition
- amino acid
- factor viii
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 41
- 150000001413 amino acids Chemical class 0.000 claims description 24
- 102100026735 Coagulation factor VIII Human genes 0.000 claims description 8
- 108010054218 Factor VIII Proteins 0.000 claims description 8
- 102000001690 Factor VIII Human genes 0.000 claims description 8
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 8
- 229960000301 factor viii Drugs 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 229940124135 Factor VIII inhibitor Drugs 0.000 claims description 6
- 102000043131 MHC class II family Human genes 0.000 claims description 6
- 108091054438 MHC class II family Proteins 0.000 claims description 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 6
- 230000030741 antigen processing and presentation Effects 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 108010051539 HLA-DR2 Antigen Proteins 0.000 claims description 4
- 208000009292 Hemophilia A Diseases 0.000 claims description 4
- 230000002209 hydrophobic effect Effects 0.000 claims description 4
- 208000013633 acquired hemophilia Diseases 0.000 claims description 3
- 238000001727 in vivo Methods 0.000 claims description 3
- 201000003542 Factor VIII deficiency Diseases 0.000 claims description 2
- 208000031220 Hemophilia Diseases 0.000 claims description 2
- 230000000903 blocking effect Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 238000003780 insertion Methods 0.000 claims description 2
- 230000037431 insertion Effects 0.000 claims description 2
- 238000012986 modification Methods 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims description 2
- 108091005601 modified peptides Proteins 0.000 claims description 2
- 238000009256 replacement therapy Methods 0.000 claims description 2
- 208000033316 Acquired hemophilia A Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 6
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0908515.0A GB0908515D0 (en) | 2009-05-18 | 2009-05-18 | Peptide |
| GB0908515.0 | 2009-05-18 | ||
| PCT/GB2010/000997 WO2010133834A2 (en) | 2009-05-18 | 2010-05-17 | Peptide |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012527440A JP2012527440A (ja) | 2012-11-08 |
| JP2012527440A5 true JP2012527440A5 (enExample) | 2013-04-18 |
| JP5784009B2 JP5784009B2 (ja) | 2015-09-24 |
Family
ID=40834163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012511336A Expired - Fee Related JP5784009B2 (ja) | 2009-05-18 | 2010-05-17 | Ｆｖｉｉｉ由来ペプチド |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US8703705B2 (enExample) |
| EP (2) | EP2465523B1 (enExample) |
| JP (1) | JP5784009B2 (enExample) |
| KR (1) | KR101673889B1 (enExample) |
| CN (1) | CN102458445B (enExample) |
| AU (1) | AU2010250957B2 (enExample) |
| BR (1) | BRPI1012845A2 (enExample) |
| CA (1) | CA2762020C (enExample) |
| CL (1) | CL2011002893A1 (enExample) |
| CO (1) | CO6460780A2 (enExample) |
| CY (1) | CY1115832T1 (enExample) |
| DK (1) | DK2465523T3 (enExample) |
| EA (1) | EA027229B1 (enExample) |
| EC (1) | ECSP11011540A (enExample) |
| ES (1) | ES2525448T3 (enExample) |
| GB (1) | GB0908515D0 (enExample) |
| HR (1) | HRP20141182T1 (enExample) |
| IL (1) | IL216199A (enExample) |
| MX (1) | MX2011012270A (enExample) |
| MY (1) | MY168207A (enExample) |
| NZ (2) | NZ613713A (enExample) |
| PL (1) | PL2465523T3 (enExample) |
| PT (1) | PT2465523E (enExample) |
| RS (1) | RS53671B1 (enExample) |
| SG (2) | SG190573A1 (enExample) |
| SI (1) | SI2465523T1 (enExample) |
| SM (1) | SMT201400186B (enExample) |
| UA (1) | UA110921C2 (enExample) |
| WO (1) | WO2010133834A2 (enExample) |
| ZA (1) | ZA201108446B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX353233B (es) | 2009-12-06 | 2018-01-08 | Bioverativ Therapeutics Inc | Polipéptidos híbridos y quiméricos del factor viii-fc, y métodos de uso de los mismos. |
| PL2917232T3 (pl) * | 2012-11-12 | 2017-09-29 | Apitope International Nv | Pochodzące od czynnika VIII peptydy do zastosowania w leczeniu hemofilii A |
| GB201314052D0 (en) * | 2013-08-06 | 2013-09-18 | Apitope Int Nv | Peptides |
| PE20231949A1 (es) | 2015-10-30 | 2023-12-05 | Spark Therapeutics Inc | VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA |
| WO2018102743A1 (en) | 2016-12-02 | 2018-06-07 | Bioverativ Therapeutics Inc. | Methods of treating hemophilic arthropathy using chimeric clotting factors |
| RS66972B1 (sr) | 2018-05-18 | 2025-07-31 | Bioverativ Therapeutics Inc | Metode lečenja hemofilije a |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1311542T1 (sl) | 2000-08-21 | 2009-02-28 | Apitope Technology Bristol Ltd | Tolerogenski peptidi |
| US20040096456A1 (en) * | 2000-12-01 | 2004-05-20 | Conti-Fine Bianca M | Method to treat hemophilia |
| AU2002312660A1 (en) * | 2001-05-31 | 2002-12-16 | D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven | Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools |
| WO2002096454A1 (en) | 2001-05-31 | 2002-12-05 | D. Collen Research Foundation Vzw | Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools |
| JP2005538694A (ja) * | 2002-04-18 | 2005-12-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 修飾されたｖｉｉｉ因子 |
| GB0723712D0 (en) * | 2007-12-04 | 2008-01-16 | Apitope Technology Bristol Ltd | Peptides |
| GB0801513D0 (en) * | 2008-01-28 | 2008-03-05 | Circassia Ltd | Peptides from factor VIII |
-
2009
- 2009-05-18 GB GBGB0908515.0A patent/GB0908515D0/en not_active Ceased
-
2010
- 2010-05-17 UA UAA201114970A patent/UA110921C2/uk unknown
- 2010-05-17 SI SI201030819T patent/SI2465523T1/sl unknown
- 2010-05-17 BR BRPI1012845A patent/BRPI1012845A2/pt not_active IP Right Cessation
- 2010-05-17 KR KR1020117028276A patent/KR101673889B1/ko not_active Expired - Fee Related
- 2010-05-17 MX MX2011012270A patent/MX2011012270A/es active IP Right Grant
- 2010-05-17 EA EA201171430A patent/EA027229B1/ru not_active IP Right Cessation
- 2010-05-17 NZ NZ613713A patent/NZ613713A/en not_active IP Right Cessation
- 2010-05-17 MY MYPI2011005515A patent/MY168207A/en unknown
- 2010-05-17 AU AU2010250957A patent/AU2010250957B2/en not_active Ceased
- 2010-05-17 NZ NZ596300A patent/NZ596300A/xx not_active IP Right Cessation
- 2010-05-17 PL PL12159740T patent/PL2465523T3/pl unknown
- 2010-05-17 DK DK12159740.5T patent/DK2465523T3/en active
- 2010-05-17 WO PCT/GB2010/000997 patent/WO2010133834A2/en not_active Ceased
- 2010-05-17 ES ES12159740.5T patent/ES2525448T3/es active Active
- 2010-05-17 EP EP12159740.5A patent/EP2465523B1/en active Active
- 2010-05-17 CA CA2762020A patent/CA2762020C/en not_active Expired - Fee Related
- 2010-05-17 US US13/320,201 patent/US8703705B2/en not_active Expired - Fee Related
- 2010-05-17 CN CN201080032337.0A patent/CN102458445B/zh not_active Expired - Fee Related
- 2010-05-17 SG SG2013030713A patent/SG190573A1/en unknown
- 2010-05-17 JP JP2012511336A patent/JP5784009B2/ja not_active Expired - Fee Related
- 2010-05-17 EP EP10721533A patent/EP2432494A2/en not_active Withdrawn
- 2010-05-17 PT PT121597405T patent/PT2465523E/pt unknown
- 2010-05-17 SG SG2011084985A patent/SG176138A1/en unknown
- 2010-05-17 RS RS20140660A patent/RS53671B1/sr unknown
-
2011
- 2011-11-07 IL IL216199A patent/IL216199A/en not_active IP Right Cessation
- 2011-11-17 ZA ZA2011/08446A patent/ZA201108446B/en unknown
- 2011-11-17 CO CO11156774A patent/CO6460780A2/es active IP Right Grant
- 2011-11-17 CL CL2011002893A patent/CL2011002893A1/es unknown
- 2011-12-16 EC EC2011011540A patent/ECSP11011540A/es unknown
-
2014
- 2014-12-06 HR HRP20141182AT patent/HRP20141182T1/hr unknown
- 2014-12-15 SM SM201400186T patent/SMT201400186B/xx unknown
- 2014-12-17 CY CY20141101057T patent/CY1115832T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011505414A5 (enExample) | ||
| JP6984898B2 (ja) | マトリックス結合ナノベシクルおよびその使用 | |
| Paunovska et al. | Using large datasets to understand nanotechnology | |
| US20200158716A1 (en) | Cell atlas of healthy and diseased barrier tissues | |
| JP2012527440A5 (enExample) | ||
| WO2017075465A1 (en) | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 | |
| Reiss et al. | Exosomes in cardiovascular disease: from mechanism to therapeutic target | |
| WO2017075478A2 (en) | Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures | |
| Stone et al. | Genomics of human fibrotic diseases: disordered wound healing response | |
| Valter et al. | Extracellular vesicles in inflammatory bowel disease: small particles, big players | |
| WO2017075451A1 (en) | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 | |
| JP2019509029A5 (enExample) | ||
| JP2020511115A5 (enExample) | ||
| JP2021523103A (ja) | Ｉｌ−３３を含有するマトリックス結合型小胞（ｍｂｖｓ）およびそれらの使用 | |
| Shih et al. | Exon-and contraction-dependent functions of titin in sarcomere assembly | |
| RU2013126581A (ru) | Мутанты стрептокиназы и их ковалентно модифицированные формы | |
| EP3749368A1 (en) | Methods of identifying and using agents for treating diseases associated with intestinal barrier dysfunction | |
| RU2015102027A (ru) | Проникающие в клетку пептиды и способы идентификации проникающих в клетку пептидов | |
| US11865168B2 (en) | Compositions and methods for treating bacterial infections | |
| Wang et al. | Hydrogel and Microgel Collaboration for Spatiotemporal Delivery of Biofactors to Awaken Nucleus Pulposus‐Derived Stem Cells for Endogenous Repair of Disc | |
| WO2020081730A2 (en) | Methods and compositions for modulating microenvironment | |
| JP2017516752A5 (enExample) | ||
| Lagan et al. | A specific form of cPRC1 containing CBX4 is co-opted to mediate oncogenic gene repression in diffuse midline glioma | |
| EP2802342A1 (en) | Peptide and uses thereof | |
| Aji et al. | Targeted delivery of Grem1 and IL-10 separately by mesenchymal stem cells effectively mitigates SETD2-deficient inflammatory bowel disease |